News: Interpace Diagnostics Group Inc (NASDAQ:IDXG) belongs to Services sector and Business Services industry. Interpace Diagnostics Group, Inc., (NASDAQ: IDXG), an organization that gives clinically valuable atomic demonstrative tests and pathology administrations for assessing dangers of tumor, proclaimed as of late that it has gotten a letter dated January 13, 2017 from the NASDAQ Listing Qualifications telling the Company that it has recaptured consistence with the necessity of the NASDAQ Stock Market to keep up a base shutting offer cost of $1.00 per share.
The letter noticed that throughout the previous 10 days from December 29, 2016 to January 12, 2017, the end offer cost of the Company’s normal stock has been at $1.00 or more noteworthy. As needs be, NASDAQ educated the Company that it has recovered consistence with Listing Rule 5550(a)(2) and that the matter was currently shut.
Independently, the Company has exhibited an arrangement to NASDAQ to recapture consistence with the NASDAQ stockholder value necessity of $2.5 Million.
Summary: Interpace Diagnostics is an organization that gives clinically helpful sub-atomic symptomatic tests and pathology administrations for assessing danger of malignancy by utilizing the latest innovation in customized drug for better patient analysis and organization. The Company directly has three popularized atomic tests; PancraGen® for the analysis and forecast of pancreatic malignancy from pancreatic pimples; ThyGenX®, for the conclusion of thyroid growth from thyroid knobs using a cutting edge sequencing measure and ThyraMIR®, for the determination of thyroid tumor from thyroid knobs using an exclusive quality expression test. Interpace Diagnostics’ main goal is to give customized pharmaceutical through atomic diagnostics and development to propel quiet care in view of thorough science.